ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADMA Adma Biologics Inc

20.11
-1.72 (-7.88%)
29 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adma Biologics Inc NASDAQ:ADMA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.72 -7.88% 20.11 20.15 20.20 21.78 19.69 21.74 4,002,265 22:00:00

Form 8-K - Current report

21/11/2024 9:30pm

Edgar (US Regulatory)



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2024

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey
 
07446
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ADMA
Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management. There are no disagreements between Mr. Fong and the Company on any matter relating to the Company’s operations, policies or practices. Mr. Fong served as a member of the Company’s Board since 2012. He also served as Chairman of the Company’s Audit Committee and a member of the Company’s Governance and Nominations Committee and Compensation Committee.

On November 19, 2024, Young T. Kwon, PhD was appointed as Chairman of the Company’s Audit Committee and designated as an “audit committee financial expert”, as such term is defined in Securities and Exchange Commission rules, Steven A. Elms was added as a member of the Company’s Audit Committee, and Alison C. Finger was added as a member of the Company’s Governance and Nominations Committee and Compensation Committee.

Item 9.01
Exhibits.

(d) Exhibits

Exhibit No.
Description
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November 21, 2024
ADMA Biologics, Inc.
   
 
By:
/s/ Adam S. Grossman
   
Name:
Adam S. Grossman
   
Title:
President and Chief Executive Officer



v3.24.3
Document and Entity Information
Nov. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 19, 2024
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

1 Year Adma Biologics Chart

1 Year Adma Biologics Chart

1 Month Adma Biologics Chart

1 Month Adma Biologics Chart

Your Recent History

Delayed Upgrade Clock